Lung Cancer
Volume 70, Issue 1 , Pages 7-13 , October 2010

Therapy of small cell lung cancer with emphasis on oral topotecan

  • Robert Pirker

      Affiliations

    • Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 1 40400 4422; fax: +43 1 40400 4461.
    • ,
  • Peter Berzinec

      Affiliations

    • Department of Oncology, Specialised Hospital of St. Zoerardus Zobor, Nitra, Slovakia
    • Co-authors according to alphabetical order.
    • ,
  • Stephen Brincat

      Affiliations

    • Sir Paul Boffa Hospital, Floriana, Malta
    • ,
  • Peter Kasan

      Affiliations

    • Department of Oncology, University Hospital Bratislava, Slovakia
    • ,
  • Gyula Ostoros

      Affiliations

    • National Korányi Institute for Tuberculosis and Pulmonology, Budapest, Hungary
    • ,
  • Milos Pesek

      Affiliations

    • Pneumology, Medical Faculty, Charles University, Plzen, Czech Republic
    • ,
  • Signe Plāte

      Affiliations

    • Riga Easten University Hospital, Riga, Latvia
    • ,
  • Gunta Purkalne

      Affiliations

    • Radiation and Chemotherapy Center, Paul Stradins Clinical University Hospital Riga, Latvia
    • ,
  • Regina Rooneem

      Affiliations

    • North Estonia Regional Hospital, Cancer Centre, Department of Chemotherapy, Tallinn, Estonia
    • ,
  • Jana Skřičková

      Affiliations

    • Department of Respiratory Diseases and TB, University Hospital, Brno, Czech Republic
    • ,
  • Dana Stanculeanu

      Affiliations

    • Institute of Oncology, Bucharest, Romania
    • ,
  • Constanta Timcheva

      Affiliations

    • Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria
    • ,
  • Valentina Tzekova

      Affiliations

    • Clinic of Chemotherapy, University Hospital Queen Joanna, ISUL, Sofia, Bulgaria
    • ,
  • Branko Zakotnik

      Affiliations

    • Division of Medical Oncology, Institute of Oncology Ljubljana, Slovenia
    • ,
  • Christoph C. Zielinski

      Affiliations

    • Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
    • ,
  • Matjaz Zwitter

      Affiliations

    • Department of Radiation Oncology, Institute of Oncology Ljubljana, Slovenia

Received 9 March 2010 ,Revised 18 May 2010 ,Accepted 23 May 2010.

References 

  1. Ferlay J, Parkiin DM, Steliarova-Foucher E. Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–781
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225–249
  3. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005;23(14):3175–3185
  4. Hansen HH. An update on management of lung cancer. Acta Oncol. 2002;41(6):500–506
  5. Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11(2):89–96
  6. Prasad US, Naylor AR, Walker WS, Lamb D, Cameron EW, Walbaum PR. Long term survival after pulmonary resection for small cell carcinoma of the lung. Thorax. 1989;44(10):784–787
  7. Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, Chansky K, et al. The International Association for the Study of Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the Tumor, Node, Metastasis Classification for Lung Cancer. J Thorac Oncol. 2007;3:1067–1077
  8. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?. Lung Cancer. 2002;37(3):271–276
  9. Rudin CM, Hann CL, Peacock CD, Watkins DN. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw. 2008;6(3):315–322
  10. Lee CB, Morris DE, Fried DB, Socinski MA. Current and evolving treatment options for limited stage small cell lung cancer. Curr Opin Oncol. 2006;18:162–172
  11. De Ruysscher D. Treatment of limited disease small cell lung cancer. Front Radiat Ther Oncol. 2010;42:173–179[Epub 2009 Nov 24]
  12. Murray N, Turrisi AT. A review of first-line treatment for small cell lung cancer. J Thorac Oncol. 2006;1:270–278
  13. Tiseo M, Ardizzoni A. Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol. 2007;2(8):764–772
  14. Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer. 1991;63(6):986–992
  15. Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39(3):303–313
  16. Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years—an analysis of 1,714 consecutive patients. J Clin Oncol. 1995;13(5):1215–1220
  17. Chute JP, Venzon DJ, Hankins L, Okunieff P, Frame JN, Ihde DC, et al. Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc. 1997;72(10):901–912
  18. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39:146–149
  19. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990;61(4):597–604
  20. Stahel RA. Diagnosis, staging, and prognostic factors of small cell lung cancer. Curr Opin Oncol. 1991;3:306–311
  21. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol. 2003;30:9–25
  22. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology. 2001;61(Suppl. 1):3–13
  23. Thatcher N, Eckardt J, Green M. Options for first- and second-line therapy in small cell lung cancer—a workshop discussion. Lung Cancer. 2003;41(Suppl. 4):S37–S41
  24. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997;89(8):577–580
  25. Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8–15
  26. Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 2000;30(1):23–36
  27. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271
  28. Aupérin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–478
  29. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–672
  30. Le Pechoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small cell cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomized clinical trial. Lancet Oncol. 2009;10:467–474
  31. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist. 2004;9(Suppl. 6):4–13
  32. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–1624
  33. Okuno SH, Jett JR. Small cell lung cancer: current therapy and promising new regimens. Oncologist. 2002;7:234–238
  34. Felip E, Stahel RA, Pavlidis N. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). Ann Oncol. 2005;16(Suppl. 1):i30–i31
  35. Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw. 2008;6(3):323–331
  36. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas Ph, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5(7):601–607
  37. Brahmer JR, Ettinger DS. Carboplatin in the treatment of small cell lung cancer. Oncologist. 1998;3:143–154
  38. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169
  39. Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 1995;13:2594–2599
  40. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91
  41. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):38–43
  42. Natale RB, Lara PN, Chansky K, Crowley JJ, Jett JR, Carleton JE, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC). J Clin Oncol. 2008;26(15S):Abstract No. 7512
  43. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24:5448–5453
  44. Yana T, Negoro S, Takada M, Yokota S, Takada Y, Sugiura T, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007;25:253–258
  45. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;(April):[Epub ahead of print]
  46. Ettinger DS. Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?. J Thorac Oncol. 2007;2:160–165
  47. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15:2090–2096
  48. Heigener DF, Freitag L, Eschbach C, Huber RM, Fink T, Hummler S, et al. Topotecan/cisplatin compared to cisplatin/etoposide for patients with extensive disease small-cell lung cancer: final results of a randomised phase III trial. J Clin Oncol. 2008;26:(May 20 Suppl.; Abstract 7513)
  49. Eckardt JR. Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy. Oncology. 2001;61(Suppl. 1):42–46
  50. Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive disease small-cell lung cancer. J Clin Oncol. 2006;24:2044–2051
  51. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:324–339
  52. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol. 1989;7(7):916–922
  53. Twelves CJ, Souhami RL, Harper PG, Ash CM, Spiro SG, Earl HM, et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer. 1990;61(1):147–150
  54. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989;59:578–583
  55. Cheng S, Evans WK, Stys-Norman D, Shepherd FA Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2007;2(4):348–354
  56. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer. V.I.2008. Available at http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf.
  57. Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol. 2003;30:72–78
  58. Johnson DH. Small cell lung cancer in the elderly patient. Semin Oncol. 1997;24:484–491
  59. Eckardt JR. Second-line treatment of small-cell lung cancer. The case for systemic chemotherapy. Oncology (Huntingt). 2003;17:191–192181–8, 191; discussion
  60. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–667
  61. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19:1743–1749
  62. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–2092
  63. O’Brien MER, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447
  64. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–2926
  65. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–115
  66. O’Brien M, Eckardt J, Ramlau R. Recent advances with topotecan in the treatment of lung cancer. Oncologist. 2007;12(10):1194–1204
  67. Eckardt JR, Ramlau R, Gervais R, Shepherd F, O’Brien M, Ciuleanu T, et al. Compliance in oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). J Clin Oncol. 2006;24(18S):Abstract No. 7092

PII: S0169-5002(10)00266-7

doi: 10.1016/j.lungcan.2010.05.020

Lung Cancer
Volume 70, Issue 1 , Pages 7-13 , October 2010

Article Tools

* Image Usage & Resolution